Company Overview

Addex Therapeutics Ltd is a clinical-stage biotechnology company focused on the discovery and development of small‑molecule allosteric modulators of G‑protein coupled receptors (GPCRs), primarily for neurological and psychiatric disorders. The company operates within the biopharmaceutical and life sciences industry, with an emphasis on central nervous system (CNS) indications where unmet medical need remains high.

The company’s core value proposition is its proprietary allosteric modulation platform, which is designed to selectively regulate GPCR activity with the goal of improved efficacy and safety compared to traditional orthosteric drugs. Addex was founded in 2002 and has evolved from an early discovery-focused organization into a development-stage company advancing both wholly owned and partnered drug candidates through preclinical and clinical development.

Business Operations

Addex Therapeutics’ operations are centered on research and development activities, with revenue historically derived from collaboration agreements, milestone payments, and licensing income, rather than commercial product sales. The company operates primarily as a single reportable business focused on drug discovery and development, without diversified commercial segments.

Key assets include its proprietary GPCR allosteric modulator discovery technology, internal drug development capabilities, and a portfolio of CNS-focused product candidates. The company conducts most R&D internally while selectively engaging in strategic partnerships with larger pharmaceutical companies to advance clinical programs. Addex operates through its principal subsidiary, Addex Therapeutics SA, which conducts substantially all operational activities.

Strategic Position & Investments

Addex’s strategy is focused on advancing a targeted pipeline of CNS programs while leveraging partnerships to offset development risk and capital requirements. Growth initiatives emphasize progressing lead candidates into later-stage clinical development and monetizing non-core programs through licensing or spin‑out structures.

Notable strategic actions include the creation of Neurosterix Ltd, a portfolio company established to house selected preclinical and clinical assets, allowing Addex to retain equity exposure while enabling focused capital allocation. The company has historically collaborated with major pharmaceutical partners on GPCR programs; however, the status and economic impact of individual collaborations may vary over time, and some prior alliances have been discontinued following strategic reviews.

Geographic Footprint

Addex Therapeutics is headquartered in Switzerland, with its principal offices located in Geneva. The company’s operations are primarily based in Europe, though its research programs and partnerships have a global scope, including interactions with clinical research organizations and pharmaceutical partners in North America and other international markets.

While Addex does not maintain large-scale international manufacturing or commercial infrastructure, its intellectual property portfolio and clinical development activities support a global market strategy aimed at major pharmaceutical territories.

Leadership & Governance

Addex Therapeutics is led by an executive team with experience in CNS drug development, biotechnology financing, and pharmaceutical partnerships. The leadership emphasizes capital discipline, scientific differentiation, and partnership-driven development as core elements of corporate strategy.

Key executives include:

• Tim Dyer – Chief Executive Officer
• John Hopkins – Chief Financial Officer
• Nick Liddle – Chairman of the Board
• Laurent Désiré – Co‑Founder and former executive; current operational role data inconclusive based on available public sources

The company is governed by a board of directors with backgrounds in biotechnology, finance, and pharmaceutical R&D, providing oversight aligned with long-term value creation and shareholder interests.